TY  - GEN
AU  - Nelson,David R
AU  - Cooper,James N
AU  - Lalezari,Jacob P
AU  - Lawitz,Eric
AU  - Pockros,Paul J
AU  - Gitlin,Norman
AU  - Freilich,Bradley F
AU  - Younes,Ziad H
AU  - Harlan,William
AU  - Ghalib,Reem
AU  - Oguchi,Godson
AU  - Thuluvath,Paul J
AU  - Ortiz-Lasanta,Grisell
AU  - Rabinovitz,Mordechai
AU  - Bernstein,David
AU  - Bennett,Michael
AU  - Hawkins,Trevor
AU  - Ravendhran,Natarajan
AU  - Sheikh,Aasim M
AU  - Varunok,Peter
AU  - Kowdley,Kris V
AU  - Hennicken,Delphine
AU  - McPhee,Fiona
AU  - Rana,Khurram
AU  - Hughes,Eric A
TI  - All-oral 12-week treatment with daclatasvir plus sofosbuvir in patients with hepatitis C virus genotype 3 infection: ALLY-3 phase III study
SN  - 1527-3350
PY  - 2015///0601
KW  - Administration, Oral
KW  - Adult
KW  - Aged
KW  - Antiviral Agents
KW  - administration & dosage
KW  - Carbamates
KW  - Drug Therapy, Combination
KW  - Female
KW  - Genotype
KW  - Hepacivirus
KW  - genetics
KW  - Hepatitis C
KW  - drug therapy
KW  - Humans
KW  - Imidazoles
KW  - Male
KW  - Middle Aged
KW  - Pyrrolidines
KW  - Sofosbuvir
KW  - Time Factors
KW  - Uridine Monophosphate
KW  - Valine
KW  - analogs & derivatives
KW  - Young Adult
N1  - Publication Type: Clinical Trial, Phase III; Journal Article; Research Support, Non-U.S. Gov't
UR  - https://doi.org/10.1002/hep.27726
ER  -